VERAXA Biotech names Carl von Halem as interim CFO Jul 10, 2026 04:05PM
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister Jul 10, 2026 04:05PM
VERAXA Biotech targets first BiTAC candidate IND-ready by 2028 Jul 6, 2026 07:01AM
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines Jul 6, 2026 07:00AM
Veraxa Biotech starts cell line development with ATUM for cancer therapy Jul 2, 2026 07:00AM


Jul 2, 2026 07:00AM VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
Jun 24, 2026 07:00AM VERAXA Biotech expands lab space at Heidelberg R&D site
Jun 24, 2026 07:00AM VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Jun 24, 2026 07:00AM VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Jun 18, 2026 07:02AM VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
Jun 18, 2026 07:00AM VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Jun 10, 2026 04:15PM VERAXA Biotech completes merger, begins NASDAQ trading
Jun 10, 2026 04:15PM VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026